Area of research
Immunology · Oncology
Research interest
Research interests include Immune cells in cancer, Cancer Immunotherapy and Biomarkers, Ferroptosis and cancer prognosis, and Glioma Diagnosis and Treatment.
Vaccine-induced T cell receptor T cell therapy targeting a glioblastoma stemness antigen
The immunology of brain tumors
Tumoral Interferon Beta Induces an Immune-Stimulatory Phenotype in Tumor-Associated Macrophages in Melanoma Brain Metastases
T cell-independent eradication of experimental glioma by intravenous TLR7/8-agonist-loaded nanoparticles
<i>In vivo</i> nanoparticle-based T cell imaging can predict therapy response towards adoptive T cell therapy in experimental glioma
INTERCEPT H3: a multicenter phase I peptide vaccine trial for the treatment of H3-mutated diffuse midline gliomas
Tumor-reactive T helper cells in the context of vaccination against glioma
A Cellular Ground Truth to Develop MRI Signatures in Glioma Models by Correlative Light Sheet Microscopy and Atlas-Based Coregistration
Dysfunctional dendritic cells limit antigen-specific T cell response in glioma
AMPLIFY-NEOVAC: a randomized, 3-arm multicenter phase I trial to assess safety, tolerability and immunogenicity of IDH1-vac combined with an immune checkpoint inhibitor targeting programmed death-ligand 1 in isocitrate dehydrogenase 1 mutant gliomas
Clinical and Translational Advances in Glioma Immunotherapy
T cell receptor dynamic and transcriptional determinants of T cell expansion in glioma-infiltrating T cells
Non-invasive tracking of T-cell recruitment to the tumor microenvironment in a murine glioma model by high field cellular MRI
A vaccine targeting mutant IDH1 in newly diagnosed glioma
Tryptophan metabolism drives dynamic immunosuppressive myeloid states in IDH-mutant gliomas
Genetically Modified Cellular Therapies for Malignant Gliomas
NIMG-48. TLR7/8-AGONIST-LOADED NANOPARTICLES REPROGRAM TUMOR-ASSOCIATED MYELOID CELLS FOR EFFECTIVE IMMUNOTHERAPY OF EXPERIMENTAL GLIOMA AND MRI-BASED TREATMENT MONITORING
KS01.3.A Tumoral MHC class II expression in gliomas drives T cell exhaustion
Abstract PR15: The oncometabolite R-2-Hydroxyglutarate suppresses the innate immune microenvironment of IDH1-mutated gliomas via aryl hydrocarbon receptor signaling
Suppression of antitumor T cell immunity by the oncometabolite (R)-2-hydroxyglutarate
Inhibition of CD95/CD95L (FAS/FASLG) Signaling with APG101 Prevents Invasion and Enhances Radiation Therapy for Glioblastoma
A mutation-specific peptide vaccine targeting IDH1R132H in patients with newly diagnosed malignant astrocytomas: A first-in-man multicenter phase I clinical trial of the German Neurooncology Working Group (NOA-16).
Vaccine Strategies in Gliomas
P04.62 The oncometabolite R-2-Hydroxyglutarate suppresses the innate immune microenvironment of IDH1-mutated gliomas via aryl hydrocarbon receptor signaling
K27M-mutant histone-3 as a novel target for glioma immunotherapy
P06.08 BRAINTuNE: Brain Tumor Neoepitope Evaluation for personalized glioma immunotherapy
OS09.9 Identification of IDH1R132H-specific T cell receptors from glioma patients and from MHC-humanized mice
OS10.2 R-2-Hydroxyglutarate shapes the immune microenvironment in IDH1-mutant gliomas
P06.06 A mutation-specific vaccine for Histone-3 K27M-mutated gliomas
Concepts in glioma immunotherapy